• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of stroke history on the risk of recurrent hip fracture or major osteoporotic fractures among patients with incident hip fracture. A nationwide cohort study
In conclusion, stroke history was associated with slightly higher risk of recurrent fracture among patients with first-time hip fracture in the overall analysis, although the confidence interval included a null result. The association was modified by baseline mobility: Pati ents with stroke history and good mobility had a markedly higher risk, whereas patients with stroke and poor mobility did not.This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - December 19, 2022 Category: Orthopaedics Authors: Thomas J. Hjelholt, S øren P. Johnsen, Peter K. Brynningsen, Grethe Andersen, Alma B. Pedersen Tags: Research Article Source Type: research

Estimating the incidence and key risk factors of cardiovascular disease in patients at high risk of imminent fracture using routinely collected real ‐world data from the UK
This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - July 12, 2022 Category: Orthopaedics Authors: Marta Pineda ‐Moncusí, Leena El‐Hussein, Antonella Delmestri, Cyrus Cooper, Moayyeri Alireza, Cesar Libanati, Emese Toth, Daniel Prieto‐Alhambra, Sara Khalid Tags: Research Article Source Type: research

Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans
ABSTRACTInhibition of sclerostin increases bone formation and decreases bone resorption, leading to increased bone mass, bone mineral density, and bone strength and reduced fracture risk. In a clinical study of the sclerostin antibody romosozumab versus alendronate in postmenopausal women (ARCH), an imbalance in adjudicated serious cardiovascular (CV) adverse events driven by an increase in myocardial infarction (MI) and stroke was observed. To explore whether there was a potential mechanistic plausibility that sclerostin expression, or its inhibition, in atherosclerotic (AS) plaques may have contributed to this imbalance,...
Source: Journal of Bone and Mineral Research - March 30, 2021 Category: Orthopaedics Authors: Gill Holdsworth, James R Staley, Peter Hall, Ian Koeverden, Ciara Vangjeli, Remi Okoye, Rogely W Boyce, James R Turk, Martin Armstrong, Alison Wolfreys, Gerard Pasterkamp Tags: Original Article Source Type: research

Sclerostin down ‐regulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans
This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - March 19, 2021 Category: Orthopaedics Authors: Gill Holdsworth, James R Staley, Peter Hall, Ian van Koeverden, Ciara Vangjeli, Remi Okoye, Rogely Waite Boyce, James R Turk, Martin Armstrong, Alison Wolfreys, Gerard Pasterkamp Tags: Original Article Source Type: research

Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score –Matched Cohort Study
ABSTRACTZoledronic acid (ZA) is an effective agent in osteoporosis and malignancy ‐related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new‐user, active comp arator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)‐matched to i...
Source: Journal of Bone and Mineral Research - November 2, 2020 Category: Orthopaedics Authors: Kristin M D'Silva, Sara Jane Cromer, Elaine W Yu, Michael Fischer, Seoyoung C Kim Tags: Original Article Source Type: research

Cardiovascular safety of denosumab across multiple indications: a systematic review and meta ‐analysis of randomized trials
AbstractThe cardiovascular safety of denosumab has not yet been evaluated in a systematic review. This systematic review and meta ‐analysis sought to quantify the number of randomized controlled trials (RCTs) of denosumab (against comparators) reporting cardiovascular adverse events (CAEs) and examine the balance of CAEs between treatment arms. MEDLINE, Embase andclinicaltrials.gov were searched from inception to 26th October 2019 for RCTs of denosumab versus comparators for any indication. Included trials were randomized, enrolled ≥100 participants and reported bone‐related outcomes. Primary outcome for analysis was...
Source: Journal of Bone and Mineral Research - August 10, 2020 Category: Orthopaedics Authors: Alexander H. Seeto, Bo Abrahamsen, Peter R. Ebeling, Alexander J. Rodr íguez Tags: Original Article Source Type: research

Acetylcholinesterase inhibitors are associated with reduced fracture risk among older Veterans with dementia
This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - November 10, 2019 Category: Orthopaedics Authors: Abayomi N. Ogunwale, Cathleen S. Colon ‐Emeric, Richard Sloane, Robert A. Adler, Kenneth W. Lyles, Richard H. Lee Tags: Original Article Source Type: research

Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
ABSTRACTWe recently showed that zoledronate prevented fractures in older women with osteopenia (hipT‐scores between −1.0 and −2.5). In addition to fewer fractures, this study also suggested that women randomized to zoledronate had fewer vascular events, a lower incidence of cancer, and a trend to lower mortality. The present analysis provides a more detailed presentation of the adverse event data from that study, a 6‐year, double‐blind trial of 2000 women aged>65  years recruited using electoral rolls. They were randomly assigned to receive four infusions of either zoledronate 5 mg or normal saline at 18�...
Source: Journal of Bone and Mineral Research - October 10, 2019 Category: Orthopaedics Authors: Ian R Reid, Anne M Horne, Borislav Mihov, Angela Stewart, Elizabeth Garratt, Sonja Bastin, Gregory D Gamble Tags: Original Article Source Type: research

Pages: 1  2